Effect and Safety Of Detrol LA In Men With Overactive Bladder Symptoms With Or Without Bladder Outlet Obstruction
Status:
Completed
Trial end date:
2006-05-01
Target enrollment:
Participant gender:
Summary
The primary objective of the trial is to evaluate the effect of tolterodine ER plus
tamsulosin versus placebo on patient perception of overall treatment benefit in men who have
frequency and urgency, with or without urinary urge incontinence (UUI), with or without
bladder outlet obstruction (BOO).
Phase:
Phase 4
Details
Lead Sponsor:
Pfizer Pfizer's Upjohn has merged with Mylan to form Viatris Inc.